Evaluation of rK-39 Strip Test Using Urine for Diagnosis of Visceral Leishmaniasis in an Endemic Region of India


Departments of Molecular Biology, Clinical Medicine, Pathology, Biostatistics, Biochemistry, Epidemiology, and Immunology, Rajendra Memorial Research Institute of Medical Sciences (Indian Council of Medical Research), Agamkuan, Patna, Bihar, India

Abstract. The definitive diagnosis of visceral leishmaniasis (VL) requires invasive procedures for demonstration of parasites in tissue smear or culture. These procedures need expertise and laboratory supports and cannot be performed in the field. The aim of the present study was to evaluate the existing rK-39 immunochromatographic nitrocellulose strips test (ICT) with some modification in human urine for diagnosis of VL. The test was performed on both sera and urine samples on the same 786 subjects (365 confirmed VL and 421 control subjects). The sensitivity of the rK-39 ICT in serum was 100%, whereas the specificity was 93.8%, 100%, and 96.2% in healthy controls from endemic, non-endemic, and other infectious diseases, respectively. However, in urine samples, the test showed 96.1% sensitivity and 100% specificity. Considering sensitivity and feasibility of the test in the field, rK-39 ICT using urine samples can be an alternative to conventional invasive VL diagnosis.

INTRODUCTION

Visceral leishmaniasis (VL) or kala-azar (KA) is a vector-borne disease caused by an intracellular protozoan parasite of the *Leishmania donovani* complex, which includes *L. donovani*, *L. infantum*, and *L. chagasi*.1 The clinical symptoms of VL include prolonged fever, hepatosplenomegaly, pancytopenia, hypergammaglobulinemia, and substantial weight loss, and they are often mimicked by malaria, typhoid fever, and tuberculosis. It is 100% fatal if left undiagnosed and untreated.2

VL still remains a serious public health problem, especially in countries of the tropical, subtropical, and Mediterranean regions, where the disease is endemic.3 The estimated annual global burden of VL is 200,000–400,000 new cases and more than 20,000–40,000 deaths, of which 90% occur in the Indian subcontinent (Bangladesh, India, and Nepal), Sudan, and Brazil.4 In the Indian subcontinent, about 200 million people are estimated to be at risk of developing VL; this region harbors an estimated 67% of the global VL disease burden.5 Bihar, an eastern Indian state, accounts for about 80% of the total burden of VL patients in India, where 33 of 38 districts are endemic.6

The confirmatory diagnosis of VL is by demonstration of leishmania parasites by Giemsa-stained smears from spleen or bone marrow and lymph node aspirates. These tests still remain the gold standard (GS) because of high specificity.7,8 The aspiration materials result in a suboptimal sensitivity ranging from 93.1–98.7% for spleen aspirates to 52–85% for bone marrow and 52–58% for lymph node aspirates. However, these methods are invasive, risky, and painful; they require skilled personnel, and they are not readily available in disease-endemic regions. Moreover, VL occurs in places where health services are poorly developed.9

Several serological tests have been developed for diagnosis of VL, such as the enzyme-linked immunosorbent assay (ELISA), the indirect immunofluorescent antibody test (IFAT), the direct agglutination test (DAT), and Western blotting.10,11 These tests have relatively good sensitivities and specificities, but they have their own limitations, including cold chain requirement, skilled personnel, expensive antigen, long incubation time, sophisticated equipment, and laboratory conditions, that prohibit the application in the field.12

The use of molecular diagnostic tools, like polymerase chain reaction (PCR) and real-time PCR, is the most accurate and sensitive way to detect leishmania parasites DNA, but these tests are cumbersome to perform and have a high cost; also, they cannot be used in field conditions. In addition, well-equipped laboratories are required for their performance.13–16

Immunochromatographic nitrocellulose strips test (ICT) is simple and widely used for rapid diagnosis of VL in human blood/serum; it is extremely sensitive and specific, and it is well-accepted at the field level.17–20 Because of this acceptance, rK-39 ICT has been introduced in the KA elimination program that was started in 2005 by the governments of three countries (Bangladesh, India, and Nepal) with the aim to reduce the annual incidence of VL to less than 1 case per 10,000 people at the subdistrict level by 2015 or earlier.21,22 The main goal of elimination program requires early diagnostic and therapeutic tools that are very easy to use and can be easily decentralized at the periphery level.23–25

Thus, for successful control of VL from the Indian subcontinent, a simple, rapid, non-invasive, and accurate field diagnostic method is needed to improve diagnosis, especially in individuals with an increased risk of suffering complications after invasive procedures.26,27 A few non-invasive sampling methods have been developed in VL diagnosis using human sputum, oral fluid, saliva, urine, and buccal swab samples with good sensitivity and specificity.28–31 Advantages of the urine rK-39 ICT are that it is simple, rapid, non-invasive, and user-friendly, it has a reliable indicator, it is easy to collect, and it does not require equipment. Additionally, the results are unambiguous with high sensitivity and specificity.28,32 Because young children are often vulnerable to VL infection, the use of urine will facilitate its use in field conditions.33

In this study, we evaluate the sensitivity and specificity of rK-39 ICT in diagnosis of VL using urine samples
from confirmed VL patients and controls compared with serum samples.

MATERIALS AND METHODS

Study design. All VL patients enrolled in this study visited the outpatient clinic of Rajendra Memorial Research Institute of Medical Sciences, Patna, Bihar, India, during the period from February of 2009 to October of 2011. These VL cases came from different endemic villages of Bihar for confirmatory diagnosis and specific treatment.

Study subjects. A total of 786 serum and urine samples were screened using ready to use rK-39 strips from 365 parasitologically confirmed VL patients and 421 control subjects. The control subjects were comprised of 162 healthy persons from the endemic areas who did not have a history of VL and 154 healthy persons from disease non-endemic areas, namely Agra and Mathura in Uttar Pradesh Province of India. Patients (N = 105) with other infections, such as tuberculosis (N = 44), malaria (N = 12), typhoid (N = 10), and leprosy (N = 39), were also enrolled in this study for assessing the specificity of the urine rK-39 strip test.

Clinical and confirmative diagnosis of VL. Suspected VL cases with a combination of clinical signs of fever (> 2 weeks duration), hepatosplenomegaly, weight loss, pancytopenia, and a positive rK-39 rapid diagnostic test for leishmania antibodies after exclusion of malaria infection (by rapid kit test) were admitted in the indoor ward for confirmative diagnosis and specific treatment. Human immunodeficiency virus (HIV) test was also performed on these patients by two rapid kits and ELISA. The confirmative diagnosis of VL was established by the demonstration of L. donovani (LD bodies) amastigotes in the splenic or bone marrow aspirate smears under the microscope. Because of ethical reasons, splenic or bone marrow aspiration could not be performed in control subjects.

Sample collection and rK-39 strip test. Peripheral blood and urine samples were collected from all participants in the study in vacutainers by puncturing antecubital veins using a 22-gauge intravenous needle and 50-mL falcon tubes, respectively. Both blood and urine samples were stored immediately in an ice box and carried to laboratory. Blood sample was centrifuged for separation of serum at the laboratory, where the rK-39 strip test was performed and interpreted according to the manufacturer’s instructions. The rK-39 strip (Kala-azar Detect; InBios International, Seattle, WA) is an immunochromatographic nitrocellulose impregnated with recombinant K-39 antigen. For the urine assay, 200 µL urine and 200 µL 10% sodium azide (equal vol/vol) solution were mixed in a fresh 1.5-mL Eppendorf tube. The rK-39 strip was dipped in the mixed urine sample (1.5-mL Eppendorf tube) without adding chase buffer, and the mixture was allowed to migrate up the strip by capillary action. After 10 minutes, the appearance of a red upper (control) band indicated the presence of immunoglobulin G (IgG) and proper test functioning; a red lower (test) band indicated the presence of anti-rK-39 IgG and a positive test result. The test was considered positive when both bands (control and test) appeared within 10 minutes and negative when only the upper control band appeared. A faint band was considered positive, whereas only a lower test band was considered an invalid test. Both blood and urine samples were collected during the same visit, and they were blinded and tested independently.

Inclusion and exclusion criteria. Inclusion criteria.

(1) Patients giving informed consent.
(2) Patients between 2 and 65 years and of both sexes.
(3) HIV-negative patients.

Exclusion criteria.

(1) Pregnant and breastfeeding females.
(2) Confection with HIV-positive patients.
(3) Patients with past history of VL and treated with antileishmanial drugs.
(4) Patients not willing to participate in the study.
(5) Patients not giving voluntary informed consent.

Chemotherapy. After clinical and confirmatory diagnosis, all VL patients were admitted in the indoor ward and treated with antileishmanial drugs as per the protocol of different clinical trials for their respective treatment regimens. Amphotericin B (AmB; Fungizone, Abbott, Mumbai, Maharashtra, India) was administered in the dose of 1 mg/kg body weight in 5% dextrose intravenously slowly over 4–6 hours for 15 injections on alternate days. Those patients who could not be given amphotericin B were treated with capsules of miltefosine for 28 days in the dose of 2.5 mg/kg body weight in two divided doses orally, except females of child-bearing age and pregnant females.

Statistical analysis. All data were entered in a computer using Excel (Version MS Office 7). Sensitivity and specificity were computed along with 95% confidence intervals (CIs) using Stata software (version 10.0).

Ethical approval. The study was approved by the Institutional Ethical Committee, and written informed consent was obtained from all participants or their legal guardian before inclusion in the study.

RESULTS

The sensitivity and specificity of the rK-39 strip test for the diagnosis of VL were evaluated with serum and urine. A total of 786 serum and urine samples from 365 parasitologically confirmed VL and 421 control subjects was tested by rK-39 strips. The serum rK-39 strip test was positive in all 365 confirmed VL subjects, whereas all 154 healthy controls from the non-endemic areas tested negative. However, 10 of 162 healthy endemic and 4 of 105 other infectious disease controls tested positive by serum rK-39. The urine rK-39 strip test was positive in 351 of 365 confirmed VL subjects, whereas all healthy controls from endemic, non-endemic areas, and other infectious diseases tested negative. Thus, the sensitivity and specificity of urine rK-39 strips were found to be 96.1% (95% CI = 93.6–97.8) and 100% (95% CI = 97–100), respectively (Table 1). k-coefficients for both serum and urine rK-39 strip tests were found to be 0.93, showing a high level of agreement.

DISCUSSION

In clinical practice as well as the ongoing KA elimination program, the rK-39 strips test has been strongly recommended on serum or finger-prick blood for rapid diagnosis of VL, but it is invasive and requires phlebotomists and sterilized needles. There is also great difficulty in sampling blood from children and healthy persons in the field because of the high proportion of refusals. Nearly one-half of VL cases occur
Comparison of sensitivity and specificity of rK-39 strip tests in diagnosis of KA using serum versus urine samples from LD body-positive VL patients and controls

<table>
<thead>
<tr>
<th>Subjects</th>
<th>Serum</th>
<th>Urine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Confirmed VL patients (for LD bodies in SA or BMA)</td>
<td>365 (96.4)</td>
<td>351 (96.1)</td>
</tr>
<tr>
<td>Healthy controls from disease-endemic areas</td>
<td>154 (97.6)</td>
<td>154 (97.0)</td>
</tr>
<tr>
<td>Healthy controls from disease non-endemic areas</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Control patients with other infections</td>
<td>105 (97.0)</td>
<td>105 (96.5)</td>
</tr>
<tr>
<td>Total</td>
<td>786 (100)</td>
<td>786 (100)</td>
</tr>
</tbody>
</table>

Other infections included tuberculosis (N = 44), malaria (N = 12), typhoid (N = 10), and leprosy (N = 39). BMA = bone marrow aspirate; NA = not applicable; SA = splenic aspirate.

CONCLUSION

GS for diagnosis of VL is invasive, hazardous, time-consuming, technically demanding, and very difficult to perform in field conditions or remote areas/primary health centers. Urine rK-39 ICT has the advantages of being safe, non-invasive, and easy to collect and perform in difficult field settings. It also can be carried out in large numbers of samples, which can prove to be a boon, especially for the diagnosis of VL in the field, and it can be used as an alternative method in the KA elimination program.

Received August 10, 2012. Accepted for publication October 6, 2012.

Published online November 13, 2012.

Acknowledgments: The authors thank the Department of Health Research (DHR), Ministry of Health and Family Welfare, Government of India, for selecting this study as a top-priority program under translational research for the elimination effort of VL from India. The authors thank Mr. Manohar Kumar (laboratory assistant) and Mr. Naresh Kumar Sinha (technical assistant) for their technical and field support in the work.

Authors’ addresses: Dharmendra Singh, Sushmita Das, Ashish Kumar, Abul Hasan Sardar, Bidyut Parikart, and Pradeep Das, Department of Molecular Biology, Rajendra Memorial Research Institute of Medical
REFERENCES


